Lablink+ Bi-directional interface for blood monitoring requirements for ^{Pr}CLOZARIL[®]



1. INTENDED USE

Lablink+ is a bi-directional interface which allows blood test results to flow electronically between CSAN[®] and Hospital Information Systems through a secure FTP server in the standard HL7 format.



Access for HCP to


results in Hospital

Information System



Hospital

Information System




Secure transfer of results

(to and from CSAN[®])

CSAN Patient Care Portal[®]

Q



Automated alert notifications generated instantly

2. ACCESS RESULTS IN THE CSAN PATIENT CARE PORTAL®

The CSAN Patient Care Portal[®] is a Canadian web-based, real-time, patient-management tool designed to assist healthcare professionals in the management of treatment-resistant schizophrenia.

CSAN[®] is the longest-running clozapine hematological monitoring program in Canada. Its range of services helps you manage the risk of agranulocytosis in patients who are taking CLOZARIL[®] by making sure that regular hematological monitoring is carried out according to the guidelines of the CLOZARIL[®] Product Monograph.

CSAN® supplies healthcare teams with notification of adverse hematological trends within 24 hours.

3. LABLINK+ KEY BENEFITS

- 16 + years developing and executing this interface technology
- · Helps reduce human error and the need to manually enter or fax results
- · Efficient use of resources and time
- Same day delivery of critical results to the CSAN Patient Care Portal[®]

4. IMPLEMENTATION SUPPORT AND MONITORING

CSAN[®] will assist with implementation:

- I/T documentation and support
- Management of implementation
- Monitoring of Lablink+ functionality daily

HLS Therapeutics Inc. 10 Carlson Court, Suite 701 Etobicoke, Ontario M9W 6L2 www.hlstherapeutics.com



Contact CSAN[®] to support your implementation or for more information at 1-800-267-2726

LOZARIE



CLOZARIL, CSAN, and CSAN Patient Care Portal + Design are all registered trademarks of Novartis AG. Pronto is a trademark of HLS Therapeutics Inc. All rights reserved. © Copyright 2021 HLS Therapeutics Inc. March 2021 MLR NS 20210301 E COM